NASDAQ · Biotechnology

ARWR (ARWR) Stock

$86.01 +1.61% NASDAQ: ARWR Healthcare

Valuation

MetricValue
Price$86.01
Market Cap$12.12B
P/E Ratio-7397.00
P/B Ratio22.36
P/S Ratio16.57
EPS (TTM)$-0.01
52-Week High$92.46
52-Week Low$14.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.43%
ROA-0.14%
ROCE19.48%
Gross Margin11.82%
Operating Margin11.82%
Net Margin-48.38%
Debt/Equity2.24
Current Ratio4.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$138.0M$243.0M$241.0M$4.0M$829.0M
Operating Profit$-149.0M$-179.0M$-205.0M$-601.0M$98.0M
Net Profit$-141.0M$-176.0M$-205.0M$-599.0M$-2.0M
EPS$-1.36$-1.67$-1.92$-5.00$-0.01
Op Margin-107.8%-73.4%-85.2%-16927.1%11.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$710.0M$692.0M$766.0M$1.1B$1.4B
Total Liabilities$301.0M$274.0M$478.0M$949.0M$882.0M
Cash$184.0M$108.0M$111.0M$103.0M$227.0M
Borrowings$26.0M$82.0M$383.0M$852.0M$366.0M

Latest News

ARWR: Lowering target price to $76.00 Argus Research · Jul 15, 2026 Arrowhead gains EU authorisation for Redemplo in evolving FCS market Clinical Trials Arena · Jul 14, 2026 Here Are Tuesday’s Best Wall Street Analyst Research Calls: Apple, Bloom Energy, Circle Internet Group, First Solar, Halliburton, IBM, Intuit, Newmont, SK hynix, and More 24/7 Wall St. · Jul 14, 2026 Stifel Initiates Arrowhead Pharmaceuticals at Buy With $98 Price Target MT Newswires · Jul 14, 2026 Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s? Barrons.com · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$171.0M$-136.0M$-154.0M$-463.0M$180.0M
Investing Cash Flow$-165.0M$-58.0M$-273.0M$-562.0M$-152.0M
Financing Cash Flow$11.0M$60.0M$250.0M$47.0M$-5.0M
Net Cash Flow$41.0M$-76.0M$3.0M$-8.0M$124.0M
Free Cash Flow$148.0M$-189.0M$-331.0M$-604.0M$157.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA86.55
FCF Yield-0.49%
Quick Ratio6.23
Interest Coverage1.10
Return 1Y406.59%
Return 3Y106.54%
Return 5Y9.72%

Ownership

Insiders Held3.68%
Institutions Held88.91%
Institutions Float Held92.30%
Institutional HolderSharesReport Date
Blackrock Inc.18,161,5192026-03-31
Avoro Capital Advisors LLC10,699,9992026-03-31
FMR, LLC7,266,6522026-03-31
Vanguard Portfolio Management LLC7,146,1362026-03-31
State Street Corporation6,496,1302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACLXArcellx, Inc. $115.07 +0.02% -28.27 $6.73B 0.00%
ALKS $50.71 -3.84% 25.87 $8.45B 0.00%
AXSM $238.37 -1.09% 38.05 $12.27B 0.00%
CRSP $46.73 +0.41% -12.98 $4.51B 0.00%
KRYS $312.57 -8.37% 42.90 $9.21B 0.00%

About ARWR

ARWR is led by CEO Christopher R. Anzalone, employs 711 people, headquartered in Pasadena, US, publicly traded since 1993.

ARWR stock trades at $86.01 with a market capitalization of $12.12B. The stock is valued at a price-to-earnings (P/E) ratio of -7397.00, price-to-book of 22.36, price-to-sales of 16.57. Over the past 52 weeks the stock has ranged between $14.30 and $92.46, and currently trades 7.0% below its 52-week high.

On profitability, ARWR generates a return on equity (ROE) of -0.43%, return on capital employed of 19.48%, an operating margin of 11.82%, a net profit margin of -48.38%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides